Abstract
Every cell is protected by a semipermeable membrane. Peptides with the right properties, for example Antimicrobial peptides (AMPs), can disrupt this protective barrier by formation of leaky pores. Unfortunately, matching peptide properties with their ability to selectively form pores in bacterial membranes remains elusive. In particular, the proline/glycine kink in helical peptides was reported to both increase and decrease antimicrobial activity. We used computer simulations and fluorescence experiments to show that a kink in helices affects the formation of membrane pores by stabilizing toroidal pores but disrupting barrel-stave pores. The position of the proline/glycine kink in the sequence further controls the specific structure of toroidal pore. Moreover, we demonstrate that two helical peptides can form a kink-like connection with similar behavior as one long helical peptide with a kink. The provided molecular-level insight can be utilized for design and modification of pore-forming antibacterial peptides or toxins.
Highlights
One of the greatest threats to global health is the emergence and spreading of bacterial strains resistant to antibiotics (Fair and Tor, 2014; WHO, 2017)
We have evaluated the effect of kink-induced flexibility on the stability of barrel-stave and toroidal pore structures
We investigated the effect of proline/glycine-induced kink in helical amphiphilic peptides on their ability to form leaky pores in model phospholid membranes
Summary
One of the greatest threats to global health is the emergence and spreading of bacterial strains resistant to antibiotics (Fair and Tor, 2014; WHO, 2017). Despite the many safety measures, resistant bacteria can be commonly found in clinical settings, causing the so-called nosocomial infections. Such infections are associated with higher hospital costs due to extended treatment, life-threatening conditions, and increased mortality. Hundreds of thousands of people die after contracting an infection caused by drug-resistant bacteria (WHO, 2017). Infections by resistant bacteria are projected to become one of the leading causes of premature death in the upcoming decades. The current rate of introducing novel antimicrobial drugs is very low and new classes of antibiotics have not been approved for decades (Nelson et al, 2019). There is a need for the development of new types of pharmaceuticals
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.